AMENDMENTS

In the Claims

Please enter the following amendments:

1. (currently amended) A pharmaceutical or veterinary composition, comprising a carrier or diluent, ~~and an active agent selected from~~ a dehydroepiandrosterone, or pharmaceutically or veterinarily acceptable salts thereof, the dehydroepiandrosterone having the chemical formula



(I);

wherein the broken line represents a single or a double bond; R is hydrogen or a halogen; the H at position 5 is present in the alpha or beta configuration or the compound of chemical formula I comprises a racemic mixture of both configurations; and R^1 is hydrogen or SO_2OM, where M is selected from H, Na, sulfatide

$$-SO_2O-CH_2CHCH_2OCOR^3; \text{ or phosphatide}$$
$$\quad\quad\quad | $$
$$\quad\quad OCOR^2$$

$$\overset{O}{\|}$$
$$-P-OCH_2CHCH_2OCOR^3,$$
$$\|\quad\quad |$$
$$O\quad OCOR^2.$$

wherein R^2 and R^3, which may be the same or different, are straight or branched (C_1-C_{14})



alkyl or glucuronide; and ~~optionally~~ a ubiquinone or pharmaceutically or veterinarily

acceptable salt thereof, wherein the ubiquinone has the chemical formula



(CoQ_n);

wherein n is 1 to 12, the agent being present in an amount effective for altering levels of, or sensitivity to, adenosine or adenosine receptors, adenosine in a subject's tissue (s), or treating bronchoconstriction, lung inflammation or allergies, chronic obstructive pulmonary disease (COPD) or a disease associated with either of them.

2. (previously presented) The composition of claim 1, wherein in the CoQ_n of formula II, wherein n is 1 to 10.

3. (previously presented) The composition of claim 1, wherein the CoQ_n of formula II, wherein n is 6 to 10.

4. (previously presented) The composition of claim 3, wherein in the CoQ_n of formula II, wherein n is 10.

5. (currently amended) The composition of claim 4, comprising about 0.1 to about 49% w/w ~~active agent~~ dehydroepiandrosterone, or pharmaceutically or veterinarily acceptable salt thereof, or a ubiquinone or pharmaceutically or veterinarily acceptable salt thereof.

6. (currently amended) The composition of claim 5, comprising about 1 to about 20% w/w ~~active agent~~ dehydroepiandrosterone, or pharmaceutically or veterinarily acceptable salt thereof, or a ubiquinone or pharmaceutically or veterinarily acceptable salt thereof.

7. (previously presented) The composition of claim 1, wherein the compound of formula (I) is dehydroepiandrosterone, where R and R^1 are each hydrogen and the broken line represents a double bond.

8. (previously presented) The composition of claim 1, wherein the compound of formula (I) is 16-alpha bromoepiandrosterone, where R is Br, and R^1 is H, and the broken line represents a double bond.

9. (previously presented) The composition of claim 1, wherein the compound of formula (I) is 16-alpha-fluoro epiandrosterone, wherein R is F, R^1 is H, and the broken line

represents a double bond.

10. (previously presented) The composition of claim 1, wherein the compound of formula (I) is etiocholanolone, wherein R and R^1 are each hydrogen and the broken line represents a double bond.

11. (previously presented) The composition of claim 1, wherein the compound of formula (I) is dehydroepiandrosterone sulfate, wherein R is H, R^1 is SO_2OM, and M is a sulfatide group as defined above, and the broken line represents a single bond.

B1 Cont

12. (previously presented) The composition of claim 1, wherein the compound of formula (I), R is halogen selected from Br, C1 or F, R^1 is H, and the broken line represents a double bond.

13. (previously presented) The composition of claim 1, wherein the compound of formula (I) is 16-alpha-fluoro epiandrosterone.

14. (previously presented) The composition of claim 1, wherein the compound of formula (I) is selected from dehydroepiandrosterone, 16-alpha-bromoepiandrosterone, 16-alpha-fluoro epiandrosterone, etiocholanolone, dehydroepiandrosterone sulfate or pharmaceutically or veterinarily acceptable salts thereof.

15. (previously presented) The composition of claim 1, wherein the carrier or diluent comprises a pharmaceutically or veterinarily acceptable carrier or diluent.

Claim 16 (withdrawn).

17. (currently amended) The composition of claim 15, further comprising ~~an agent selected from~~ a folinic acid, a pharmaceutically or veterinarily acceptable salts of folinic acid, ~~other therapeutic agents~~, a preservatives, a antioxidants, a flavoring agents, a volatile oils, a buffering agents, a dispersants or a surfactants.

18. (previously presented) The composition of claim 15, which is a systemic or topical formulation.

19. (currently amended) The ~~formulation~~ composition of claim 18, wherein said composition is in the form of a formulation selected from buccal, sublingual, dermal, intraocular, vaginal, rectal, intraarticular, intrapulmonary respirable, oral, inhalable, nasal, topical, parenteral, or transdermal.

20. (currently amended) The ~~formulation~~ composition of claim 19, ~~which~~ wherein

said composition is an oral formulation selected from the group consisting of capsules, cachets, lozenges, tablets, powder, granules, solution, suspensions and emulsions.

21. (currently amended) The ~~oral formulation~~ composition of claim 19, wherein said composition is an oral formulation which is a solution, suspension or emulsion selected from the group consisting of aqueous and non-aqueous liquid solutions and suspensions and oil-in-water and water-in-oil emulsions.

22. (currently amended) The ~~oral formulation~~ composition of claim 19, wherein said composition is an oral formulation which is a buccal or sub-lingual formulation selected from the group consisting of lozenges further comprising a flavoring agent selected from the group consisting of sucrose, acacia and tragacanth; and pastilles further comprising an inert base selected from the group consisting of gelatin, glycerin, sucrose and acacia.

23. (currently amended) The ~~oral formulation~~ composition of claim 20, furthers comprising an enteric coating.

24. (currently amended) The ~~formulation~~ composition of claim 1, ~~which~~ wherein said composition is a parenteral formulation.

25. (currently amended) The ~~parental formulation~~ composition of claim 24, is in an injectable form.

26. (currently amended) The ~~parental formulation~~ composition of claim 24, ~~selected from~~ wherein said parenteral formulation is a subcutaneous, intradermal, intramuscular, or intravenous formulations.

27. (currently amended) The ~~injectable formulation~~ composition of claim 24, ~~selected from~~ wherein said parenteral formulation is an injectable solutions or suspensions, and ~~which may~~ further ~~comprise~~ comprising a folinic acid, pharmaceutically or veterinarily acceptable salts thereof, ~~other therapeutic agents,~~ antioxidants, buffers, or bacteriostatic agents or solutes which renders the injectable solution or suspension isotonic with the blood of ~~any intended recipient~~ said subject.

28. (currently amended) The ~~injectable formulation~~ composition of claim 27, wherein the injectable solutions or suspensions ~~are selected from~~ a sterile aqueous or non-aqueous injection solutions or suspensions~~, which may further comprise suspending agents or thickening agents~~.

29. (previously presented) The composition of claim 1 in bulk or in single or multi-dose form.

30. (previously presented) The composition of claim 29, wherein the single or multi-dose forms is provided in sealed ampoules or vials.

31. (previously presented) The composition of claim 1, which is freeze-dried or lyophilized.

B' Cont

32. (currently amended) The ~~formulation~~ composition of claim 19, ~~which~~ wherein said composition is a topical formulation selected from ointments, creams, lotions, pastes, gels, sprays, aerosols or oils, which may further comprise a carrier selected from vaseline, lanoline, polyethylene glycols, alcohols or trans-dermal enhancers.

33. (currently amended) The ~~formulation~~ composition of claim 19, ~~which~~ wherein said composition is a transdermal formulation in the form of a patch.

34. (currently amended) The ~~transdermal formulation~~ composition of claim 33, which is an iontophoretic formulation selected from iontophoretic solutions or suspensions, and which may further comprise a buffer.

35. (currently amended) The ~~formulation~~ composition of claim 19, ~~which~~ wherein said composition is an inhalable, respirable, intrapulmonary or nasal formulation.

36. (currently amended) The ~~inhalable or respirable formulation~~ composition of claim 35, ~~which~~ wherein said composition is an aerosol or spray comprising liquid or solid particles of the active agent, and which ~~may~~ further comprises an ingredient selected from folinic acid, other therapeutic agents, preservatives, antioxidants, flavoring agents, volatile oils, buffering agents, dispersants or surfactants.

37. (currently amended) The ~~formulation~~ composition of claim 36, comprising an inhalable or respirable formulation comprising powdered or liquid particles of the active agent about 0.05 to about 10 μ in size.

38. (currently amended) The ~~formulation~~ composition of claim 37, comprising an inhalable or respirable aerosol formulation comprising powdered or liquid particles of the active agent about 0.1 to about 5 μ in size.

39. (currently amended) The ~~formulation~~ composition of claim 36, which comprises a nasal or intrapulmonary aerosol formulation comprising powdered or liquid particles of the

active agent about 10 to about 100 μ in size.

40. (currently amended) The ~~formulation~~ composition of claim 39, which comprises powdered or liquid particles of the active agent about 10 to about 50 μ in size.

41. (currently amended) The ~~formulation~~ composition of claim ~~16~~ 15, wherein the carrier comprises a hydrophobic carrier.

B1 Cont'd

42. (currently amended) A kit comprising the ~~formulation~~ composition of claim 15, and a delivery device.

43. (currently amended) The kit of claim 42, wherein the ~~formulation~~ composition comprises an inhalable, respirable, intrapulmonary or nasal formulation, and the delivery device comprises an inhaler provided with an aerosol generating means.

44. (currently amended) The kit of claim 42, wherein the delivery device delivers individual pre-metered doses of the ~~formulation~~ composition.

45. (previously presented) The kit of claim 42, wherein the delivery device comprises an inhaler.

46. (previously presented) The kit of claim 42, wherein the inhaler comprises a nebulizer or insufflator.

47. (currently amended) The kit of claim 42, wherein the delivery device comprises a compression inhaler, and the ~~formulation~~ composition comprises a suspension or solution in an aqueous or non-aqueous liquid or an oil-in-water or water-in-oil emulsion.

48. (currently amended) The kit of claim 41, wherein the ~~formulation~~ composition is provided in a pierceable or openable capsule or cartridge.

Claims 49-79 (withdrawn).